ORYX

5 articles about ORYX

• ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model

  11/11/2019

  ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, reported new results on the mode of action of oncolytic virus ParvOryx in human ovarian cancer explants.

• ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx

  11/4/2019

  Endorsement of pivotal development program in recurrent glioblastoma (rGBM) from both EMA and FDA

• ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer

  10/30/2019

  ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today published positive clinical trial results from a dose-escalating Phase I/IIa trial with oncolytic virus ParvOryx in metastatic, inoperable pancreatic cancer.

• ORYX Reports Positive Clinical Evidence With Oncolytic Virus ParvOryx In Combination With Immuno-Oncology Drugs

  5/23/2017

• ORYX Enrolls First Patients In A Dose-Escalating Phase I/IIa Pilot Study With Oncolytic Virus Parvoryx To Treat Metastatic Pancreatic Cancer

  4/4/2016